Gibran
Development of adaptive, nature-inspired artificial intelligence systems for applications such as drug discovery, utilizing small datasets.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $2.6m | Seed | |
| Total Funding | 000k | ||
Related Content
Gibran, an AI research startup, was co-founded by Govind Balakrishnan and Srikant Chakravarti, who were also the founders of Curio. The company recently secured $2.6 million in a seed funding round from Together Fund.
Gibran is focused on developing a new generation of adaptive, scale-free AI systems. Their approach involves merging large language models (LLMs) with nature-inspired systems, aiming to create models that can operate effectively with small datasets. This is particularly relevant for applications such as drug discovery. The company's research is also informed by the founders' previous work, including a notable paper in the journal Nature.
The company's business model is centered on AI research and the development of these specialized AI systems. Their target market includes sectors that can benefit from AI models that are not reliant on massive datasets, such as the pharmaceutical and life sciences industries for drug discovery and research.
Keywords: artificial intelligence, machine learning, drug discovery, adaptive AI, nature-inspired AI, small-data AI, LLMs, AI research, seed funding, Curio founders